Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk's business model focuses on the development, manufacturing, and marketing of pharmaceutical products and services. The company operates through two main segments: Diabetes and Obesity Care, and Biopharmaceuticals.
Novo Nordisk's product portfolio includes a range of insulin products, GLP-1 recep...
NovoRapid is classified as a Star. This fast-acting insulin product has a strong market share and is experiencing significant market growth. Its leadership in the insulin market is supported by its efficacy and a broad patient base. The rising prevalence of diabetes globally and NovoRapid's established reputation contribute to its robust growth.
Tresiba falls into the Star category. This long-acting insulin product has a substantial market share and is growing steadily. Its flexibility in dosing and long duration of ...
Our BCG tool allows you to fill out the matrix with your own products.
It's like ChatGPT but for your university course. Ask questions about your course material and get instant answers with citations.